why choose us

First received: March 24, 2023

Clinical Trial: Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Metastatic Lung Non-Small Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Trial of Cemiplimab Alone for Untreated Brain Metastases From PD-L1 ? 50% Non-Small Cell Lung Cancer

Brief Summary: This phase II trial tests how well cemiplimab works in treating patients with PD-L1 >= 50% non-small cell lung cancer (NSCLC) that has spread from where it first started (primary site) to the brain (metastases).Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases and another 30% develop brain metastases during the illness.Currently, the management of brain metastases relies on stereotactic radiosurgery (SRS), which has high rates of local control, but in combination with…

Read more